A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

For this study, we are looking for adults aged 18 or over. You must have been diagnosed with multiple myeloma and have measurable levels of the disease. This means your doctors can track how your myeloma is responding to treatment using blood or urine tests.

Your multiple myeloma must have either returned after previous treatments or not responded adequately to your most recent therapy. You will also need to have a specific genetic change in your myeloma cells, called a t(11;14) translocation, which your doctor can check with a special test.

Depending on which part of the study you might join, there are different requirements for how many previous treatments you've had. For some parts, you will need to have had at least three prior treatments, including specific types of drugs. For other parts, having had one or more prior treatments might be enough. Your overall health and organ function (like your blood counts and kidney function) also need to be good enough to take part.

If you decide to take part in this study, you will receive the study medication (sonrotoclax and/or other approved drugs) as instructed by the research team. This will involve regular visits to the clinic for medical check-ups, blood and urine tests, and other assessments like bone marrow samples. These tests help doctors monitor your health, how the treatment is working, and if you experience any side effects.

The frequency and duration of your visits will depend on which part of the study you are in and how you respond to treatment. You will be closely monitored throughout the study. The total duration of your participation will vary, but it involves ongoing treatment and follow-up to ensure your safety and to understand the long-term effects of the medication.